Trial Profile
A dose-response study with strontium malonate in postmenopausal women. A 12 week, multi national, double blind, randomized, 5 arms, parallel group placebo controlled open label active controlled, phase II study with 3 dose levels of strontium malonate and Protelos within post menopausal women with a BMDT-score below -1
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Strontium malonate (Primary)
- Indications Bone resorption; Menopause; Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Acronyms STRONG
- 11 Dec 2006 New trial record.